Antios Therapeutics' hep B candidate gets another round of applause from investors, closing out a $171M megaround
Antios Therapeutics, the Atlanta biotech that was the brainchild of former hep C pioneer Pharmasset executive and former Antios CEO Abel De La Rosa, announced this morning that the biotech raised $75 million in a Series B-1, ending the firm’s Series B round.
After the biotech threw its hat into the hepatitis B ring three years ago with $25 million from a Series A, Antios then raised $96 million from a Series B in April to push their lead candidate — an active site polymerase inhibitor nucleotide, or ASPIN known as ATI-2173 — through Phase II. The latest $75 million round brings the company’s Series B up to $171 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.